Synthetic peptide derived from an internal region of the human BMPR-1A (bone morphogenetic protein receptor type 1A, Serine/threonine protein kinase receptor R5 (SKR5), activin receptor-like kinase-3 (ALK-3)), which differs from mouse and rat BMPR-1A by one nonconservative amino acid replacement.
Conjugate
Unconjugated
Form
Liquid
Concentration
0.25 mg/ml
Purification
Antigen affinity chromatography
Storage buffer
PBS, pH 7.4
Preservative
0.1% sodium azide
Storage Conditions
-20°C
Tested Applications
Dilution *
Immunoprecipitation (IP)
Assay Dependent
Western Blot (WB)
Assay Dependent
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Background/Target Information
The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. BMPRIA binds BMP4 with high-affinity in solution and is a potent BMP-4 antagonist in vitro. In adult tissues, BMPRIA is widely expressed, with the highest expression levels detected in skeletal muscle. BMPRIA is also widely expressed during embryogenesis.
原厂资料:
注意事项:
For Research Use Only. Not for use in diagnostic procedures.